{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:44:27Z","timestamp":1777934667985,"version":"3.51.4"},"reference-count":59,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This review discusses current strategies, new advancements and clinical trials for the treatment of bone metastases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>\n                      We performed a narrative review using literatures obtained from PubMed and Google Scholar using the terms such as \u201cProstate cancer\u201d, \u201cbone metastases\u201d, \u201ctreatment\u201d. The search included articles between 2000 and 2024. For clinical trial information, we searched\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"www.clincialtrial.gov\">www.clincialtrial.gov<\/jats:ext-link>\n                      and included trials of Prostate cancer and bone metastases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>We go through the mechanisms of action, clinical effectiveness, and limitations of current and emerging therapies, including bisphosphonates, Receptor activator of nuclear factor kappa-\u0392 ligand (RANKL) inhibitors, novel agents and Prostate-Specific Membrane Antigen (PSMA) targeted approaches. By examining recent research and ongoing clinical trials, we seek to inform the development of optimized treatment strategies and guide future research directions. The review discuss about novel agents such as Radium-223 and Lutetium-177. Lutetium-177 is emerging as a promising treatment for metastatic prostate cancer with bone involvement. These treatment options offer significant survival benefits in patients with bone-dominant metastatic prostate cancer. The review also explores combination treatments, where integrating bone-targeted therapies with systemic prostate cancer treatments holding potential for enhanced efficacy. Ongoing clinical trials investigating novel treatment options and advanced drug delivery techniques are highlighted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The advancements signify a promising direction in the treatment of bone metastases in prostate cancer, highlighting the need for continuous innovation to enhance patient care and outcomes<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552251350621","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T03:54:02Z","timestamp":1750391642000},"page":"1307-1315","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacological management of prostate cancer-bone metastasis and recent advancements: A comprehensive review"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9929-4449","authenticated-orcid":false,"given":"Muhammed","family":"Munavvir","sequence":"first","affiliation":[{"name":"Yenepoya Medical College Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Asadur Rahman","sequence":"additional","affiliation":[{"name":"Yenepoya Medical College Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mujeeburahiman","family":"M","sequence":"additional","affiliation":[{"name":"Yenepoya Medical College Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1191"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/hp.2000.6698"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.44"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/02692163080220011602"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-006-0203-x"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-023-01417-x"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2010.090299"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-012470862-4\/50008-8"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21196985"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2008.03.018"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-018-0480-6"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/418340"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/biom11111643"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e328335729c"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh141"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20308"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001822"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-007-0540-8"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/02841860902874748"},{"key":"e_1_3_3_21_2","volume-title":"StatPearls","author":"Ganesan K","year":"2024","unstructured":"Ganesan K, Goyal A, Roane D. Bisphosphonate. In: StatPearls. Treasure Island, FL: StatPearls Publishing, 2024. [Updated 2023 Jul 3]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470248\/."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2405"},{"key":"e_1_3_3_23_2","first-page":"24","article-title":"Bisphosphonates for advanced prostate cancer","volume":"1","author":"Macherey S","year":"2017","unstructured":"Macherey S, Monsef I, Jahn F, et al. Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev 2017; 1: 24.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_24_2","volume-title":"StatPearls","author":"Hildebrand GK","year":"2024","unstructured":"Hildebrand GK, Patel P, Kasi A. Denosumab. In: StatPearls. Treasure Island, FL: StatPearls Publishing, 2024. [Updated 2024 Feb 28]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK535388\/."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.7101"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756287216686018"},{"key":"e_1_3_3_27_2","first-page":"16","article-title":"Improvement in health status and quality of life in patients with osteoporosis treated with denosumab: results at a mean follow-up of six years","volume":"26","author":"Mercurio M","year":"2022","unstructured":"Mercurio M, Familiari F, de Filippis R, et al. Improvement in health status and quality of life in patients with osteoporosis treated with denosumab: results at a mean follow-up of six years. Eur Rev Med Pharmacol Sci 2022; 26: 16\u201323.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-35308-z"},{"key":"e_1_3_3_29_2","article-title":"Severe, prolonged, denosumab-induced hypocalcemia with recovery after 111 days of high-dose calcium supplementation","volume":"5","author":"McCaleb RV","year":"2019","unstructured":"McCaleb RV, Johnson JT. Severe, prolonged, denosumab-induced hypocalcemia with recovery after 111 days of high-dose calcium supplementation. AACE Clin Case Rep 2019; 5: e82\u2013e85.","journal-title":"AACE Clin Case Rep"},{"key":"e_1_3_3_30_2","unstructured":"FDA adds Boxed Warning for increased risk of severe hypocalcemia in patients with advanced chronic kidney disease taking osteoporosis medicine Prolia (denosumab). FDA https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-adds-boxed-warning-increased-risk-severe-hypocalcemia-patients-advanced-chronic-kidney-disease (2024)."},{"key":"e_1_3_3_31_2","article-title":"Cost-Effectiveness analysis of denosumab in the prevention of skeletal-related events among patients with breast cancer with bone metastasis in India","volume":"10","author":"Wadhwa R","year":"2024","unstructured":"Wadhwa R, Gupta N, Dixit J, et al. Cost-Effectiveness analysis of denosumab in the prevention of skeletal-related events among patients with breast cancer with bone metastasis in India. JCO Glob Oncol 2024; 10: e2300396.","journal-title":"JCO Glob Oncol"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5262"},{"key":"e_1_3_3_33_2","unstructured":"Highlights of prescribing information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/203971lbl.pdf."},{"key":"e_1_3_3_34_2","volume-title":"Radium-223 for patients with castration resistant prostate cancer with bone metastases: a review of clinical effectiveness, cost-effectiveness and guidelines","author":"Canadian Agency for Drugs and Technologies in Health","year":"2016","unstructured":"Canadian Agency for Drugs and Technologies in Health. Radium-223 for patients with castration resistant prostate cancer with bone metastases: a review of clinical effectiveness, cost-effectiveness and guidelines. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health, 2016. APPENDIX 10, Guidelines and Recommendations for Radium-223 for Treatment of Patients with Bone Metastatic CRPC, https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK401498\/."},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw065"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.183194"},{"key":"e_1_3_3_37_2","first-page":"5","article-title":"Antibody-drug conjugates in prostate cancer: a systematic review","volume":"15","author":"Sardinha M","year":"2023","unstructured":"Sardinha M, Dos Reis AF, Barreira JV, et al. Antibody-drug conjugates in prostate cancer: a systematic review. Cureus 2023; 15: 5.","journal-title":"Cureus"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-022-00891-1"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265448"},{"key":"e_1_3_3_41_2","unstructured":"Medsurge India. [cited 2024 Dec 19]. https:\/\/medsurgeindia.com\/nuclear-medicine-therapy\/lu%20psma\/ (2023)."},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-021-01649-w"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2010.11.003"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2019.119558"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.5570"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30860-X"},{"key":"e_1_3_3_47_2","unstructured":"Tombal BF Loriot Y Saad F et al. Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333\/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: an interim safety analysis."},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-3583-1"},{"key":"e_1_3_3_49_2","unstructured":"US National Library of Medicine. ClinicalTrials.gov. [cited 2024 Dec 19] https:\/\/clinicaltrials.gov\/study\/NCT05740488."},{"key":"e_1_3_3_50_2","unstructured":"US National Library of Medicine. ClinicalTrials.gov. [cited 2024 Dec 19] https:\/\/clinicaltrials.gov\/study\/NCT06008483."},{"key":"e_1_3_3_51_2","unstructured":"US National Library of Medicine. ClinicalTrials.gov. [cited 2024 Dec 19] https:\/\/clinicaltrials.gov\/study\/NCT04754425."},{"key":"e_1_3_3_52_2","unstructured":"US National Library of Medicine. ClinicalTrials.gov. [cited 2024 Dec 19] https:\/\/clinicaltrials.gov\/study\/NCT04549207."},{"key":"e_1_3_3_53_2","unstructured":"US National Library of Medicine. ClinicalTrials.gov. [cited 2024 Dec 19] https:\/\/clinicaltrials.gov\/study\/NCT03395197."},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.3310\/nihropenres.13284.2"},{"key":"e_1_3_3_55_2","unstructured":"eMedicine. Imaging in bone metastases: practice essentials radiography computed tomography https:\/\/emedicine.medscape.com\/article\/387840-overview (2019)."},{"key":"e_1_3_3_56_2","first-page":"4","article-title":"The physiology of bone blood flow: a review","volume":"88","author":"McCarthy I","year":"2006","unstructured":"McCarthy I. The physiology of bone blood flow: a review. JBJS 2006; 88: 4\u20139.","journal-title":"JBJS"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2010.10.004"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2018.06.007"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2017.10.053"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23765"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251350621","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552251350621","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251350621","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:31:19Z","timestamp":1777689079000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552251350621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":59,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1177\/10781552251350621"],"URL":"https:\/\/doi.org\/10.1177\/10781552251350621","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]}}}